Doxil and Gemcitabine in Recurrent Ovarian Cancer

• Status: Terminated
• Trial end date: 2006-05-01
• Target enrollment: 0
• Participant gender: Female

Summary

Standard treatment for recurrent ovarian cancer is chemotherapy with one or more drugs. One of these drugs, Doxil, can cause skin toxicity at the standard dosages. This study investigates using a lower dose given more frequently in combination with a second drug Gemcitabine.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Women and Infants Hospital of Rhode Island
• Collaborator: Ortho Biotech, Inc.
• Treatments: Doxorubicin; Gemcitabine; Liposomal doxorubicin

Criteria

Inclusion Criteria:

• recurrent platinum resistant ovarian cancer

• measurable disease

Exclusion Criteria:

• prior treatment with Doxil or Gemzar

• life expectancy <3months

• cardiac ejection fraction <50%